Trial Profile
A study evaluating the addition of rituximab or bortezomib to Rabbit antithymocyte globulin (rATG) for mixed acute rejection treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Oct 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Rituximab (Primary) ; Antithymocyte globulin
- Indications Transplant rejection
- Focus Therapeutic Use
- 15 Oct 2016 New trial record